World Health Organization. Fact sheet: dementia. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed 14 Nov 2022.

Alzheimer’s Disease International. World Alzheimer report 2021: journey through the diagnosis of dementia. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf. Accessed March 2023.

Jellinger KA. Recent update on the heterogeneity of the Alzheimer’s disease spectrum. J Neural Transm. 2022;129:1–24.

Article  CAS  PubMed  Google Scholar 

DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.

Article  PubMed  PubMed Central  Google Scholar 

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.

Article  PubMed  Google Scholar 

Villain N, Dubois B. Alzheimer’s disease including focal presentations. Semin Neurol. 2019;39:213–26.

Article  PubMed  Google Scholar 

Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59:1764–7.

Article  PubMed  Google Scholar 

Scharre DW. Preclinical, prodromal, and dementia stages of Alzheimer’s disease: indentifying the correct stage of Alzheimer’s disease helps in managing risk, diagnosis, and management decisions. https://practicalneurology.com/articles/2019-june/preclinical-prodromal-and-dementia-stages-ofalzheimers-disease. Accessed 15 Nov 2022.

Rasmussen J, Langerman H. Alzheimer’s disease - why we need early diagnosis. Degener Neurol Neuromuscul Dis. 2019;9:123–30.

PubMed  PubMed Central  Google Scholar 

Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8:e12295.

Article  PubMed  Google Scholar 

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer’s disease and genetic risk. Cortex. 2007;43:835–45.

Article  PubMed  Google Scholar 

Sarazin M, Chauviré V, Gerardin E, Colliot O, Kinkingnéhun S, de Souza LC, et al. The amnestic syndrome of hippocampal type in Alzheimer’s disease: an MRI study. J Alzheimers Dis. 2010;22:285–94.

Article  PubMed  Google Scholar 

Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13–36.

Article  Google Scholar 

Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.

Article  PubMed  PubMed Central  Google Scholar 

Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13:870–84.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.

Article  PubMed  PubMed Central  Google Scholar 

Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138:2732–49.

Article  PubMed  PubMed Central  Google Scholar 

Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Ann Neurol. 2018;84:729–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minoshima S, Cross D, Thientunyakit T, Foster NL, Drzezga A. 18F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies. J Nucl Med. 2022;63:2s–12s.

Article  CAS  PubMed  Google Scholar 

Koga S, Josephs KA, Aiba I, Yoshida M, Dickson DW. Neuropathology and emerging biomarkers in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022;93:919–29.

Article  PubMed  Google Scholar 

Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67.

Article  PubMed  PubMed Central  Google Scholar 

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. National Institute on Aging and Alzheimer’s Association (NIA-AA) Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.

Article  PubMed  PubMed Central  Google Scholar 

Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Petersen RC, Hu WT, et al. Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer’s disease. Mov Disord. 2010;25:1246–52.

Article  PubMed  PubMed Central  Google Scholar 

Pillai JA, Bonner-Jackson A, Bekris LM, Safar J, Bena J, Leverenz JB. Highly elevated cerebrospinal fluid total tau level reflects higher likelihood of non-amnestic subtype of Alzheimer’s disease. J Alzheimers Dis. 2019;70:1051–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J. Multiplex immunoassay measurement of amyloid-beta(42) to amyloid-beta(40) ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease. Exp Brain Res. 2018;236:1241–50.

Article  CAS  PubMed  Google Scholar 

Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benedet AL, Brum WS, Hansson O, Karikari TK, Zimmer ER, Zetterberg H, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14:26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo MC, Dickerson MC, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021;20:222–34.

Article  PubMed  PubMed Central  Google Scholar 

Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021;17:580–9.

Article  PubMed  Google Scholar 

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.

Article  CAS  PubMed  Google Scholar 

Wolk DA. Amyloid imaging in atypical presentations of Alzheimer’s disease. Curr Neurol Neurosci Rep. 2013;13:412.

Article  PubMed  Google Scholar 

Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829–39.

Article  PubMed  Google Scholar 

Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of elevated amyloid and Tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2022;79:975–85.

Article  PubMed  PubMed Central  Google Scholar 

Mecca AP, Chen MK, O’Dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET. Alzheimers Dement. 2020;16:974–82.

Article  PubMed  PubMed Central  Google Scholar 

Werry EL, Bright FM, Piguet O, Ittner LM, Halliday GM, Hodges JR, et al. Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int J Mol Sci. 2019;20:3161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vemuri P, Jack CR Jr. Role of structural MRI in Alzheimer’s disease. Alzheimers Res Ther. 2010;2:23.

Article  PubMed  PubMed Central  Google Scholar 

Stebbins GT, Murphy CM. Diffusion tensor imaging in Alzheimer’s disease and mild cognitive impairment. Behav Neurol. 2009;21:39–49.